Frazis Capital Podcast

• Why markets look “fine” but small caps are quietly crashing

• The brutal 50 - 60% wipeouts in quantum, nuclear & neo-cloud stocks

• How 2025 became a one-way market dominated by AI & semiconductors

• AI CapEx, rate expectations, and why headlines are driving everything

• OpenAI vs Google Gemini vs Claude, who’s actually winning the AI race?

• The uncomfortable truth about Nvidia demand and “financed revenue”

• Neo-clouds explained: why leasing GPUs may signal weakness, not strength

• The looming AI oversupply risk nobody wants to talk about

• Why hyperscalers (Microsoft, Amazon) always win in compute cycles

• How our risk models cut exposure before major drawdowns

• Shorting as a defensive tools, reducing risk without timing the market

• Why US biotech quietly became one of the best-performing sectors

• GLP-1 drugs, oral weight-loss meds & the next healthcare rotation

• Software stocks at cycle lows, where 2–3x upside could emerge

• Why fintech and payments keep disappointing investors

• “Compounder” crashes: Nike, Lululemon & the end of premium multiples

• Aussie tech pain: Xero, WiseTech & massive valuation resets

• Defence, drones & insider selling, what signals really matter

• What would actually trigger the next broad market sell-off

• Our 2026 setup: where risk is rising and where opportunity is forming

0:00 – Intro: Mike & Ellianna catch up after Melbourne investor meetings

0:45 – Market update: Retail investors driving a red-hot rally

2:15 – Quants, institutions, and semiconductors hitting profit targets

3:40 – Why Frazis Capital is rotating into healthcare

4:30 – Spotlight on Grail: $10B spent chasing a pan-cancer blood test

6:10 – The Pathfinder 2 trial and physician skepticism

7:40 – FDA approval, adoption challenges, and cash burn9:00 – Clarity Pharmaceuticals: $203M raise and bold head-to-head trial

10:40 – Lessons from biotech cycles: Intellia’s 100% rebound

12:10 – Quant signals, timing, and managing risk in volatile markets

13:40 – Retail euphoria vs. institutional lag — what comes next?

15:10 – AI investment boom: data centers, semis, and software plays

17:00 – Byrna’s results & the “AI in everything” trend

18:20 – When hype meets fundamentals: the AMD-OpenAI deal

20:00 – Scaling out, profit-taking, and managing portfolio exposure

22:10 – Wrap-up and next week’s preview

00:00 – Intro & welcome to Chris Burns, CEO of Amplia
02:00 – Why pancreatic cancer is so deadly & hard to diagnose
06:30 – Current treatment options: Gem/Abraxane vs FOLFIRINOX
11:20 – Side effects & challenges with chemotherapy
15:00 – Why pancreatic cancer is difficult to treat (fibrosis & mutations)
19:00 – Amplia’s approach: FAK inhibitors and how they work
23:00 – History of FAK inhibitors & Amplia’s drug development story
27:00 – ACCENT trial design and early results (response rate, PFS)
32:00 – Complete responses & long-term responders (12–18+ months)
36:00 – Next steps: Simplicity trial with FOLFIRINOX
38:30 – Path to registrational trial & FDA fast track
41:00 – Combination opportunities: KRAS inhibitors & ADCs
43:00 – Commercial strategy, pricing, partnerships
44:30 – Wrap-up & final thoughts

Syntara’s highly anticipated Phase 2 results in myelofibrosis—what the data tells us, why the market sold off, and what might come next in terms of funding or partnership.

Learn more at: www.fraziscapitalpartners.comNvidia’s Q1 PerformanceImpact of the H20 Chip Ban on ChinaMary Meeker: Big Tech CapEx TrendsAutonomous Driving in San Francisco: Waymo vs. UberLidar vs. Vision Debate and Safety ImplicationsLidar Startup Failures and Industry FalloutSpaceX Starship Test Flight & 2026 Mars Launch WindowHumanoid Robots and Potential Economic ImpactAI Attention Economy & ChatGPT vs. Google SearchDeveloper Growth in Google’s EcosystemAWS CapEx Dynamics & Nvidia as Key Beneficiary

HIMS, NU, MELI, AMD & Aussie Biotech

Anteris CEO explains why their new biomimetic heart valve can take serious market share in a $10 billion market. It's currently implanted in over 100 patients, and surgeons are delighted with the results. The market is sleeping on this one...

Mike and Ellianna discuss

#87 - Google earnings, and was that a low in semis and biotech? Mike and Ellianna discuss

Mike and Ellianna discuss the latest market moves.Sections00:00 - US Tariffs and Market Reactions06:35 - Managing Risk12:41 - Opportunities in Tech and Healthcare21:18 - Reddit23:54 - Market Dynamics and Short Selling28:54 - Clarity's Market Position and Future Prospects33:43 - Biotech Sector Valuation and Mispricing35:55 - Interest Rates and Economic Implications39:50 - Future Investment Strategies and Growth Opportunities